PATENT CLAIM ANALYSIS

Application Number: 16065498
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "279000"]

Abstract:
This invention relates to a combination of gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate (chemical name: 2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-[phenyl (benzoxy-L-alaninyl)] phosphate) (NUC-1031) and a platinum-based anticancer agent selected from cisplatin, picoplatin, lipoplatin and triplatin. The combinations are useful in the treatment of cancer, particularly biliary tract and bladder cancer.

Claim (Index 18):
The method of  claim 14 , wherein the gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate is in the form of the free base.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 94.0
- Lexical Diversity: 1.36957
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15308475', '15753237', '15308491', '15514673', '13254108']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8047887056212609
- 35 USC 102 Novelty (BERT): 0.5263712651461112
- Combined Prediction Score: 0.776946961573746
- Mean Citation Score: 298.313084
- Max Citation Score: 341.05823
- Similarity Product: 261.1664749372047

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test